CT
Crystalys Therapeutics
United States · Biotech · Healthtech · Enterprise software
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $130M | Cormorant Asset Management — Role not disclosedFrazier Life Sciences — Role not disclosedHBM Healthcare Investments — Role not disclosedKCap Biotechnology Fund — Role not disclosedNovo Holdings — Role not disclosedPivotal bioVenture Partners — Role not disclosedSoleus Capital — Role not disclosedSR One — Role not disclosedTrails Edge Capital Partners — Role not disclosedWellington Management — Role not disclosed |